This is a double blind, placebo controlled, add-on clinical trial, of levetiracetam efficacy
and safety, in epilepsy cluster seizure.
Efficacy is evaluated in the range of 2 to 24 hours after taking the tablet. If the patient
has a seizure during this interval, he is considered as a non-respondent patient.